CAPR
vs
S&P 500
CAPR
S&P 500
Over the past 12 months, CAPR has significantly outperformed S&P 500, delivering a return of +108% compared to the S&P 500's +15% growth.
Stocks Performance
CAPR vs S&P 500
Performance Gap
CAPR vs S&P 500
Performance By Year
CAPR vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Capricor Therapeutics Inc
Glance View
Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. The company is headquartered in Beverly Hills, California and currently employs 48 full-time employees. The company went IPO on 2002-06-04. The firm consists of cell therapy program, including CAP-1002 for Duchenne Muscular Dystrophy program and CAP-1002 with CAP-1002 for coronavirus (COVID-19). The Company’s lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is in clinical development for treating Duchenne muscular dystrophy and the cytokine storm associated with COVID-19. Capricor is also developing its exosome technology therapeutic platform. The firm is focused on developing exosomes capable of delivering nucleic acids, including messenger RNA (mRNA) as well as proteins, to treat or prevent a range of diseases. CAP-1002 cell therapy programs initiated Pivotal Phase III, HOPE-3.